Triple agonist research compound for GLP-1, GIP, and glucagon receptor pathway studies.

Original guide dosage

Original guide range: start 0.5-1 mg/week, titrate gradually toward 4-12 mg/week where research protocols support it.

Original frequency

Weekly injection

Original cycle

12-48+ weeks with gradual titration

Updated evidence review

Updated literature range: peer-reviewed human studies report once-weekly SC retatrutide arms from 0.5 mg to 12 mg, with 2026 top-line phase 3 obesity reporting 4 mg, 9 mg, and 12 mg weekly over 80 weeks. Public guide wording should not present this as a self-use instruction.

New vs old dosage comparison

Old guide: start 0.5 to 1 mg/week and titrate toward 4 to 12 mg/week. New research check: old range broadly aligns, but add the documented 0.5 mg study arm and the 9 mg phase 3 target dose as research-study arms.

Route / format

SC in clinical development reporting

Frequency

Once weekly in late-stage obesity development

Cycle logic

Long continuous treatment windows, 24 to 80 plus weeks in reported development, not short cycles

Why this cycle label

Efficacy and tolerability were measured over months with dose escalation to reduce gastrointestinal adverse effects.

How to read both ranges

Kept from the previous guide. The updated review confirms the stronger evidence is long, continuous weekly escalation rather than short cycles.

Evidence level

Randomized phase 2 and phase 3 reporting

Monitoring / safety notes

GI tolerance, hydration, weight trajectory, glucose context, gallbladder or pancreatitis-class symptoms. Nausea, vomiting, diarrhea, constipation, appetite suppression, dehydration risk, and class-style gallbladder or pancreatitis concerns.

COA check

Verify salt form, purity, and identity against batch COA.

Storage

Store according to product label, COA, and laboratory SOPs

Higher-capacity triple agonist research compound for metabolic signalling and documentation workflows.

Original guide dosage

Original guide range: start 0.5-1 mg/week, titrate gradually toward 4-12 mg/week where research protocols support it.

Original frequency

Weekly injection

Original cycle

12-48+ weeks with gradual titration

Updated evidence review

Updated literature range: 0.5 mg, 4 mg, 8 mg, and 12 mg once weekly appear in peer-reviewed human arms; 2026 top-line phase 3 obesity reporting also describes 4 mg, 9 mg, and 12 mg weekly over 80 weeks.

New vs old dosage comparison

Old guide: start 0.5 to 1 mg/week and titrate toward 4 to 12 mg/week. New research check: keep the old range, add 0.5 mg as a documented study arm and 9 mg as a newly reported phase 3 target arm.

Route / format

SC in clinical development reporting

Frequency

Once weekly

Cycle logic

24 to 80 plus week evidence windows, not a short pulse cycle

Why this cycle label

Long metabolic endpoints and dose-related gastrointestinal tolerability require staged escalation.

How to read both ranges

Same practical guide range as the 10mg size, with the updated evidence label shown separately.

Evidence level

Randomized phase 2 and phase 3 reporting

Monitoring / safety notes

GI tolerance, hydration, weight trajectory, glucose context, gallbladder or pancreatitis-class symptoms. Dose-related gastrointestinal effects are the main tolerability concern.

COA check

Same evidence base as Retatrutide 10mg. Verify batch COA.

Storage

Store according to product label, COA, and laboratory SOPs

Extended-capacity triple agonist research vial for longer research documentation timelines.

Original guide dosage

Original guide range: start 0.5-1 mg/week, titrate gradually toward 4-12 mg/week where research protocols support it.

Original frequency

Weekly injection

Original cycle

12-48+ weeks with gradual titration

Updated evidence review

Updated literature range: 0.5 mg, 4 mg, 8 mg, and 12 mg once weekly appear in peer-reviewed human arms; 2026 top-line phase 3 obesity reporting also describes 4 mg, 9 mg, and 12 mg weekly over 80 weeks.

New vs old dosage comparison

Old guide: start 0.5 to 1 mg/week and titrate toward 4 to 12 mg/week. New research check: keep the old range, add 0.5 mg as a documented study arm and 9 mg as a newly reported phase 3 target arm.

Route / format

SC in clinical development reporting

Frequency

Once weekly

Cycle logic

24 to 80 plus week evidence windows, not a short pulse cycle

Why this cycle label

Long continuous treatment matches the clinical development model.

How to read both ranges

Same practical guide range as the smaller sizes, with higher vial capacity for longer research timelines.

Evidence level

Randomized phase 2 and phase 3 reporting

Monitoring / safety notes

GI tolerance, hydration, weight trajectory, glucose context, gallbladder or pancreatitis-class symptoms. Dose-related gastrointestinal effects are the main tolerability concern.

COA check

Same evidence base as smaller Retatrutide catalogue sizes. Verify batch COA.

Storage

Store according to product label, COA, and laboratory SOPs

GHRH analogue research material used in growth hormone axis and visceral adiposity pathway studies.

Original guide dosage

Original guide range: 1-2 mg/day.

Original frequency

Daily or 5 days on / 2 days off

Original cycle

8-12 weeks on, with breaks

Updated evidence review

Approved EGRIFTA WR formulation: 1.28 mg SC once daily.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

SC

Frequency

Daily

Cycle logic

Continuous treatment with reassessment; evidence supports 26 weeks and longer with monitoring

Why this cycle label

The evidence base is ongoing daily treatment, not bodybuilding-style short cycling.

How to read both ranges

Kept as historical guide context. Updated evidence highlights 1.28 mg SC once daily for current EGRIFTA WR formulation with monitoring.

Evidence level

Official prescribing information

Monitoring / safety notes

IGF-1, fasting glucose or HbA1c, malignancy history, injection-site tolerance. Arthralgia, edema, myalgia, injection-site reactions, glucose intolerance; contraindications include active malignancy and pregnancy.

COA check

Verify exact formulation because approved EGRIFTA WR dosing is formulation-specific.

Storage

Store according to product label, COA, and laboratory SOPs

Selective GH secretagogue research material used in receptor interaction and endocrine signalling studies.

Original guide dosage

Original guide range: 100-300 mcg, 1-2x/day.

Original frequency

5-7 days/week, often pre-bed or AM/PM

Original cycle

8 weeks on, 4-8 weeks off

Updated evidence review

No validated chronic human wellness dose established.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

IV or SC in small human studies

Frequency

Chronic retail-vial frequency is not evidence-based

Cycle logic

No validated chronic retail cycle

Why this cycle label

Available human data do not validate long wellness or physique cycles.

How to read both ranges

Kept as previous practical guide context. Updated evidence flags no validated chronic wellness dose.

Evidence level

Small human studies; low to moderate evidence for acute endocrine response

Monitoring / safety notes

GH-axis exposure, IGF-1, glucose context, edema, headache, appetite changes. Potential GH-axis overexposure, edema, headache, increased appetite.

COA check

Published human evidence is mainly acute GH-challenge and PK-PD work.

Storage

Store according to product label, COA, and laboratory SOPs

Combined GHRH/GHRP research blend for pulse signalling and receptor interaction models.

Original guide dosage

Original guide range: 100-300 mcg each, 1-2x/day.

Original frequency

5-7 days/week

Original cycle

8 weeks on / 4-8 weeks off

Updated evidence review

Uncertain. Exact commercial blend and CJC variant are not directly validated by standalone literature.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

Usually SC in research-vial context

Frequency

Formulation dependent

Cycle logic

Uncertain; depends on CJC variant and ratio

Why this cycle label

DAC-containing CJC favors longer spacing; no-DAC/mod-GRF theory favors pulsatile use. The blend itself lacks direct validation.

How to read both ranges

Kept as previous guide context. Updated evidence notes uncertainty depends on the exact CJC variant and blend ratio.

Evidence level

Indirect evidence only

Monitoring / safety notes

IGF-1, glucose context, edema, headache, appetite, formulation verification. GH-axis related adverse effects and blend uncertainty.

COA check

Guide must confirm whether CJC component is DAC or no-DAC and verify ratio.

Storage

Store according to product label, COA, and laboratory SOPs

Long-acting GHRH analogue with DAC modification for extended signalling research.

Original guide dosage

Original guide range: 1-2 mg once or twice weekly.

Original frequency

1-2x/week

Original cycle

8-12 weeks

Updated evidence review

Weight-based weekly SC dosing was studied; no validated fixed retail-vial regimen.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

SC

Frequency

Weekly or longer interval fits long half-life

Cycle logic

Small-study endocrine use only; no validated retail cycle

Why this cycle label

DAC pharmacology supports infrequent dosing rather than repeated daily pulses.

How to read both ranges

Kept as practical guide context. Updated evidence notes no validated fixed retail-vial regimen.

Evidence level

Small human endocrine studies

Monitoring / safety notes

IGF-1, glucose context, fluid retention, endocrine response. GH-axis related effects and long-acting exposure uncertainty.

COA check

Verify DAC modification, exact sequence, and batch purity.

Storage

Store according to product label, COA, and laboratory SOPs

hGH fragment research material studied for lipolysis and metabolic pathway signalling.

Original guide dosage

Original guide range: 250-500 mcg daily.

Original frequency

5 days on / 2 days off

Original cycle

8 weeks

Updated evidence review

Daily dosing was studied, but no durable evidence-based practical dose range is established from this review.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

Varied in development; SC in retail-vial context is not a validated rule

Frequency

Daily exposure was studied historically

Cycle logic

Human obesity trials ran 12 to 24 weeks; efficacy was limited and development halted

Why this cycle label

Existing trials do not support confident practical recommendation.

How to read both ranges

Kept as historical guide context. Updated review says human trial evidence is weak for a confident recommendation.

Evidence level

Human trials existed, but weak practical evidence

Monitoring / safety notes

Metabolic markers, study endpoint response, product identity. Do not present as established weight-loss protocol.

COA check

Commonly identified as hGH 176-191 fragment. Verify sequence against COA.

Storage

Store according to product label, COA, and laboratory SOPs

Body Protection Compound research material used in tissue, tendon, ligament, and gut barrier models.

Original guide dosage

Original guide range: 250-500 mcg daily.

Original frequency

Daily

Original cycle

4-8 weeks

Updated evidence review

No validated human dose established. New literature check found animal PK ranges only: 20 micrograms/kg IV; 20, 100, or 500 micrograms/kg IM; and repeated 100 micrograms/kg IM for 7 days in rats/dogs.

New vs old dosage comparison

Old guide: 250 to 500 mcg daily. New research check: do not replace the old practical range with animal microgram/kg data because it is not a validated human regimen. Show it as preclinical context only.

Route / format

Experimental SC or oral marketed routes are not clinically validated; animal PK used IV/IM

Frequency

No validated human frequency

Cycle logic

Grey-market 2 to 6 week cycles are not clinical standards

Why this cycle label

Popularity comes mainly from animal and mechanistic literature, not validated human dosing.

How to read both ranges

Kept as common practical guide range. Updated evidence says no validated human dose is established.

Evidence level

Mostly animal data; very limited human evidence

Monitoring / safety notes

Product quality, sterility, injection reaction, study endpoint documentation. Product-quality uncertainty, injection reactions, and theoretical tissue-growth/angiogenic signaling concerns.

COA check

Pentadecapeptide reference material; verify CAS and sequence against batch COA.

Storage

Store according to product label, COA, and laboratory SOPs

Thymosin beta research peptide used in systemic tissue repair and mobility models.

Original guide dosage

Original guide range: 2-5 mg weekly.

Original frequency

1-2 injections weekly

Original cycle

4-8 weeks

Updated evidence review

No validated human dose established for TB-500 itself.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

Experimental SC in retail-vial context

Frequency

No validated frequency

Cycle logic

4 to 8 week cycles are anecdotal only

Why this cycle label

Direct human therapeutic evidence for TB-500 itself is extremely weak.

How to read both ranges

Kept as common practical guide range. Updated evidence says TB-500-specific human evidence is extremely weak.

Evidence level

Extremely weak direct human evidence

Monitoring / safety notes

Product quality, sterility, injection reaction, study endpoint documentation. Product-quality uncertainty and injection reaction risk.

COA check

Verify fragment identity and purity against COA.

Storage

Store according to product label, COA, and laboratory SOPs

Research blend combining BPC-157 and TB-500 for recovery pathway studies.

Original guide dosage

Original guide range: 250-500 mcg each, total 500-1000 mcg daily.

Original frequency

Daily

Original cycle

4-8 weeks

Updated evidence review

No validated fixed-blend human dose. New literature check reinforces that BPC-157 component data is preclinical/animal and not directly translatable to a blend dose.

New vs old dosage comparison

Old guide: 250 to 500 mcg each, total 500 to 1000 mcg daily. New research check: no direct blend study confirms that range; keep it as old guide context only.

Route / format

Usually SC if used as an injectable blend

Frequency

Varies; no validated frequency

Cycle logic

4 to 8 week pragmatic cycle only, not clinical standard

Why this cycle label

Tissue remodeling is multi-week, but the exact fixed blend lacks direct clinical validation.

How to read both ranges

Kept as previous blend guide context. Updated evidence says fixed-blend human dosing is not validated.

Evidence level

Indirect component evidence only

Monitoring / safety notes

Local reaction, product quality/sterility, symptom or model endpoint change. Blend-specific long-term safety uncertain.

COA check

Blend component ratio must be verified against supplied documentation.

Storage

Store according to product label, COA, and laboratory SOPs

Research blend combining BPC-157, TB-500, and GHK-Cu for tissue and extracellular matrix studies.

Original guide dosage

Original guide range: 2-5 mg total blend/day.

Original frequency

Daily or 5 days on / 2 days off

Original cycle

4-8 weeks

Updated evidence review

No validated fixed-blend human dose established. New literature check adds that BPC-157 is preclinical-dominant and GHK-Cu data is mostly in vitro/topical animal work.

New vs old dosage comparison

Old guide: 2 to 5 mg total blend/day. New research check: no fixed-blend human dose was established; keep old range only as historical guide context.

Route / format

Usually SC if used as injectable blend

Frequency

Varies; no validated frequency

Cycle logic

Pragmatic 4 to 8 weeks only

Why this cycle label

Multi-week tissue-remodeling rationale exists, but the fixed blend lacks direct clinical validation.

How to read both ranges

Kept as previous blend guide context. Updated evidence says no validated fixed-blend human dose.

Evidence level

Indirect component evidence only

Monitoring / safety notes

Local reaction, symptom change, product quality and sterility. Injection reactions and blend-specific long-term safety uncertainty.

COA check

Blend component amounts must be verified against product label and COA.

Storage

Store according to product label, COA, and laboratory SOPs

Advanced research blend combining GHK-Cu, BPC-157, TB-500, and KPV.

Original guide dosage

Original guide range: 2-5 mg total blend/day.

Original frequency

5 days on / 2 days off

Original cycle

8 weeks

Updated evidence review

No validated fixed-blend human dose. New literature check reinforces that GHK-Cu, BPC-157, and KPV component evidence does not validate this fixed blend as a human dose protocol.

New vs old dosage comparison

Old guide: 2 to 5 mg total blend/day. New research check: no direct KLOW fixed-blend regimen established; keep old range as historical guide context only.

Route / format

Formulation dependent

Frequency

Varies; no validated frequency

Cycle logic

4 to 8 week heuristic only, not validated

Why this cycle label

Component biology is plausible, but the fixed blend has no direct clinical validation.

How to read both ranges

Kept as previous blend guide context. Updated evidence says no validated fixed-blend human dose.

Evidence level

Indirect component evidence only

Monitoring / safety notes

Local reaction, irritation, product quality, sterility, endpoint documentation. Blend-specific long-term safety uncertain.

COA check

Blend component amounts must be verified against product label and COA.

Storage

Store according to product label, COA, and laboratory SOPs

Copper tripeptide research material used in collagen, skin matrix, and repair pathway studies.

Original guide dosage

Original guide range: 1-2 mg daily by research route or topical format.

Original frequency

Daily

Original cycle

4-8 weeks

Updated evidence review

Updated literature check: accessible GHK-Cu data is mainly picomolar-to-nanomolar in vitro activity plus daily topical animal wound work over 13 days. No robust therapeutic human dose-finding range was recovered.

New vs old dosage comparison

Old guide: 1 to 2 mg daily by research route or topical format. New research check: keep the old guide as historical/practical context only; the new evidence does not validate a universal mg dose and points to concentration-dependent topical research.

Route / format

Topical evidence is stronger than injectable evidence

Frequency

Topical once or twice daily in cosmetic practice, formulation dependent

Cycle logic

Continuous topical use as tolerated; exact strength must be confirmed

Why this cycle label

Topical studies use repeated local application rather than finite injection cycles.

How to read both ranges

Kept as previous guide context. Updated evidence is strongest for topical concentration-dependent use, not a universal mg application standard.

Evidence level

Small controlled topical studies / cosmeceutical evidence

Monitoring / safety notes

Skin tolerance, irritation, pigmentary changes, catalogue concentration. Irritation, sensitivity, possible pigmentary changes.

COA check

Copper-binding tripeptide; verify exact molecular data against COA.

Storage

Store according to product label, COA, and laboratory SOPs

Topical copper peptide cream positioned around skin barrier support, collagen signalling, and visible skin-quality research workflows.

Original guide dosage

Practical topical reference range: apply a thin, even layer 1-2x daily.

Original frequency

Once or twice daily

Original cycle

4-12 week observation window or ongoing as tolerated

Updated evidence review

Concentration-dependent topical application. Exact strength should be confirmed from the live product specification.

New vs old dosage comparison

Practical topical reference kept: thin, even layer 1 to 2 times daily, with a 4 to 12 week observation window or ongoing as tolerated.

Route / format

Topical

Frequency

Usually once or twice daily in topical product research or cosmetic practice

Cycle logic

4 to 12 week topical observation window, or ongoing as tolerated

Why this cycle label

Barrier repair and collagen remodelling are gradual, so repeated application across weeks is the relevant observation model.

How to read both ranges

Added from the image-based usage guide so the topical product keeps its practical reference wording alongside the research review.

Evidence level

Topical / cosmeceutical evidence, not injectable dose evidence

Monitoring / safety notes

Skin tolerance, irritation, sensitivity, and visible skin-response documentation. Avoid broken-skin use unless specifically studied. Monitor irritation.

COA check

Confirm exact cream size, concentration, and batch specification from the live catalogue.

Storage

Store according to product label, COA, and laboratory SOPs

Topical GHK-Cu style scalp serum positioned around follicle-environment support, scalp quality, and hair-support research themes.

Original guide dosage

Practical topical reference range: apply to scalp once or twice daily.

Original frequency

Once or twice daily

Original cycle

8-16+ weeks because hair-cycle outcomes are slow

Updated evidence review

Concentration-dependent topical application. No validated universal mg dose.

New vs old dosage comparison

Practical topical reference kept: apply to scalp once or twice daily; assess over 8 to 16 plus weeks because hair-cycle outcomes are slow.

Route / format

Topical

Frequency

Usually once or twice daily in topical scalp routines

Cycle logic

8 to 16 plus week observation window for hair or scalp outcomes

Why this cycle label

Hair-cycle biology is slow, so short trials are unlikely to show meaningful changes.

How to read both ranges

Added from the image-based usage guide so scalp and follicle-support workflows are not missed.

Evidence level

Low to moderate topical rationale; hair-specific evidence is weaker than skin evidence

Monitoring / safety notes

Scalp irritation, dryness, sensitivity, and visible hair or scalp response. Monitor scalp irritation, dryness, and sensitivity.

COA check

Confirm exact serum concentration and application specification from the live catalogue.

Storage

Store according to product label, COA, and laboratory SOPs

Alpha-MSH derived tripeptide research material used in inflammation and gut barrier models.

Original guide dosage

Original guide range: 250-500 mcg daily.

Original frequency

5 days on / 2 days off

Original cycle

8 weeks

Updated evidence review

No validated systemic human dose established.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

Experimental topical, oral, or SC routes discussed

Frequency

No validated frequency

Cycle logic

Any 2 to 8 week cycle is extrapolative

Why this cycle label

Mechanistic and preclinical evidence does not establish a human dosing protocol.

How to read both ranges

Kept as previous guide context. Updated evidence says no validated systemic human dose.

Evidence level

Mostly preclinical / mechanistic evidence

Monitoring / safety notes

Study endpoints, irritation or local reaction, product identity. Human systemic safety and dose standardization are not established.

COA check

Tripeptide sequence Lys-Pro-Val; verify molecular data against COA.

Storage

Store according to product label, COA, and laboratory SOPs

Antimicrobial peptide research material used in immune modulation and tissue repair studies.

Original guide dosage

Original guide range: 100-500 mcg daily.

Original frequency

Daily

Original cycle

2-6 weeks

Updated evidence review

No validated systemic human dose established.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

Experimental local, topical, or injectable routes

Frequency

No validated frequency

Cycle logic

No validated cycle

Why this cycle label

Clinical translation is constrained by bioavailability, stability, and formulation issues.

How to read both ranges

Kept as previous guide context. Updated evidence says no validated systemic human dose.

Evidence level

Mechanistic and preclinical emphasis; human dosing absent

Monitoring / safety notes

Local reaction, immune/inflammatory response markers, product identity. Systemic human dosing and safety remain under-standardized.

COA check

Verify exact synthetic fragment and purity against COA.

Storage

Store according to product label, COA, and laboratory SOPs

Nicotinamide adenine dinucleotide research material used in mitochondrial, redox, and cellular energy studies.

Original guide dosage

Original guide range: 50-100 mg daily or 2-3x/week; slow IV protocols vary.

Original frequency

2-5x/week, start low in research documentation

Original cycle

As needed, often ongoing low-dose in clinic-style protocols

Updated evidence review

No validated injectable human dose range established in this review.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

IV most often in clinics; IM/SC less standardized

Frequency

No validated cycle standard

Cycle logic

Clinic protocols vary widely and are not well anchored by high-quality dose-response trials

Why this cycle label

Strong biochemistry does not equal standardized injectable dose evidence.

How to read both ranges

Kept as previous guide context. Updated evidence says injectable NAD+ dosing lacks standardization.

Evidence level

Low evidence for injectable NAD+; stronger biology than dosing data

Monitoring / safety notes

Infusion rate tolerance, flushing, nausea, chest/abdominal pressure, documentation of protocol. Flushing, nausea, chest or abdominal pressure, and rate-related discomfort in infusion settings.

COA check

CAS 53-84-9. Molecular formula C21H27N7O14P2. Molecular weight approx. 663.43 g/mol.

Storage

Store according to product label, COA, and laboratory SOPs

Mitochondrial-targeting peptide research material used in oxidative stress and cellular protection studies.

Original guide dosage

Original guide range: 500-1000 mcg daily.

Original frequency

Daily or 5 days on / 2 days off

Original cycle

8 weeks

Updated evidence review

Updated literature check for elamipretide/SS-31: FDA-labeled Forzinity regimen is 40 mg SC once daily in Barth syndrome patients weighing at least 30 kg, with 20 mg SC once daily in adults with severe renal impairment not on dialysis. This is indication-specific and not a universal retail-vial rule.

New vs old dosage comparison

Old guide: 500 to 1000 mcg daily. New research check: the official elamipretide label is mg-scale and far higher, but it is disease-label specific. Keep the old guide visible as historical context and flag the official 40 mg/20 mg data separately.

Route / format

SC in FDA-labeled Barth syndrome product; IV used in some interaction studies

Frequency

Once daily in FDA label; other protocols are indication dependent

Cycle logic

Structured medical protocols, often weeks to months

Why this cycle label

Formal development uses indication-specific protocols rather than casual short stacks.

How to read both ranges

Kept as previous guide context. Updated evidence says formal regimens are indication-specific mg-scale protocols.

Evidence level

Clinical development exists; exact regimen depends on indication

Monitoring / safety notes

Condition-specific protocol verification, local reactions, study endpoint markers. Injection-site reactions and protocol-specific adverse events.

COA check

Also known as elamipretide in literature. Verify batch data against COA.

Storage

Store according to product label, COA, and laboratory SOPs

Tetrapeptide research material studied in telomerase and cellular ageing models.

Original guide dosage

Original guide range: 1-5 mg daily, with some protocols up to 10 mg.

Original frequency

Daily for 10-20 days

Original cycle

Repeat 2-3x/year

Updated evidence review

No globally validated human dose established in accessible English-primary evidence.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

Usually IM or SC in marketed practice, but not globally standardized

Frequency

Short-course use is commonly described regionally

Cycle logic

Short-course use described, evidence standardization poor

Why this cycle label

Regional literature and mechanistic claims do not establish a universal dose.

How to read both ranges

Kept as previous guide context. Updated evidence says no globally validated human dose is established.

Evidence level

Low evidence; regional / in vitro emphasis

Monitoring / safety notes

Study documentation, product identity, adverse reactions. Long-term and standardized human safety evidence limited.

COA check

Tetrapeptide Ala-Glu-Asp-Gly; verify COA for exact details.

Storage

Store according to product label, COA, and laboratory SOPs

Mitochondria-derived peptide research material used in metabolic flexibility and energy pathway studies.

Original guide dosage

Original guide range: 5-10 mg, 2-3x/week, or 1-5 mg daily microdose.

Original frequency

Morning or pre-workout in research-style guide context

Original cycle

8 weeks

Updated evidence review

No validated human therapeutic dose established.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

Experimental SC in retail-vial context

Frequency

No validated frequency

Cycle logic

Any exercise-mimetic cycle is speculative

Why this cycle label

Mechanistic literature is interesting, but robust human dosing has not been standardized.

How to read both ranges

Kept as previous guide context. Updated evidence says no validated human therapeutic dose.

Evidence level

Mostly animal / mechanistic evidence

Monitoring / safety notes

Metabolic markers, product identity, study endpoint response. Human dose standardization and safety are not established.

COA check

Verify exact sequence and molecular data against COA.

Storage

Store according to product label, COA, and laboratory SOPs

ACTH analogue research material used in cognitive, neuroprotective, and focus pathway studies.

Original guide dosage

Original guide range: 300-1000 mcg daily.

Original frequency

2-3 days/week or in cycles

Original cycle

8 weeks on / 8 weeks off

Updated evidence review

Intranasal formulations 0.1% to 1% are documented regionally; no robust internationally standardized mg/day regimen retrieved.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

IN is the main evidence anchor

Frequency

Typically short daily courses in regional practice

Cycle logic

Short daily course; exact international standard lacking

Why this cycle label

Regional product form is intranasal, not fixed injectable self-dosing.

How to read both ranges

Kept as previous guide context. Updated evidence anchors regional intranasal formulations rather than fixed injectable mg/day.

Evidence level

Regional clinical use plus preclinical mechanism

Monitoring / safety notes

Focus, mood, sleep, headache, nasal irritation. Local irritation, headache, stimulation/sedation mismatch.

COA check

Verify analogue format and sequence against COA.

Storage

Store according to product label, COA, and laboratory SOPs

Tuftsin-derived peptide research material used in stress, mood, and cognitive pathway studies.

Original guide dosage

Original guide range: 250-500 mcg daily, up to 1000 mcg/day in divided research doses.

Original frequency

Daily or 5 days on / 2 days off

Original cycle

10-30 days, repeat as needed

Updated evidence review

Main evidence anchor is 0.15% intranasal aqueous formulation; fixed injectable dosing is not standardized.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

IN

Frequency

Daily in regional short-course use

Cycle logic

Short daily course, often 10 to 30 days

Why this cycle label

Regional clinical use supports daily intranasal short courses more than intermittent weekly use.

How to read both ranges

Kept as previous guide context. Updated evidence supports daily short-course intranasal use more than intermittent dosing.

Evidence level

Regional clinical evidence; low to moderate

Monitoring / safety notes

Mood response, sleep quality, nasal tolerance. Usually mild; local irritation, headache, variable stimulation or sedation.

COA check

Verify exact sequence and molecular data against COA.

Storage

Store according to product label, COA, and laboratory SOPs

Short neuropeptide research material used in neuronal protection and healthy ageing studies.

Original guide dosage

Original guide range: 1-3 mg daily.

Original frequency

Daily

Original cycle

10-20 days

Updated evidence review

No globally validated human dose established.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

Usually IM or SC in marketed practice, not globally standardized

Frequency

Short-course use described regionally

Cycle logic

Short-course use described, evidence sparse

Why this cycle label

Regional literature does not establish an internationally standardized dose.

How to read both ranges

Kept as previous guide context. Updated evidence remains low and regionally based.

Evidence level

Low evidence; regional literature

Monitoring / safety notes

Study documentation, product identity, adverse reactions. Standardized human safety evidence limited.

COA check

Tripeptide Glu-Asp-Arg; verify against batch COA.

Storage

Store according to product label, COA, and laboratory SOPs

Delta Sleep-Inducing Peptide research material used in circadian and sleep architecture research.

Original guide dosage

Original guide range: 100-300 mcg before sleep.

Original frequency

5 days on / 2 days off or as needed

Original cycle

8 weeks

Updated evidence review

No validated human dose established.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

IV, IM, IN, or SC described historically, but not standardized

Frequency

No reliable standard

Cycle logic

No reliable cycle standard

Why this cycle label

Literature is contradictory and receptor biology remains unsettled.

How to read both ranges

Kept as previous guide context. Updated evidence says no reliable validated human dose or cycle.

Evidence level

Very low evidence; contradictory literature

Monitoring / safety notes

Sleep quality markers, next-day sedation, product identity. Dose and safety standardization are not established.

COA check

Nonapeptide reference material; verify exact sequence and COA.

Storage

Store according to product label, COA, and laboratory SOPs

Melanocortin analogue research material used in pigmentation and UV-response pathway studies.

Original guide dosage

Original guide range: 250-1000 mcg daily.

Original frequency

Daily loading, then maintenance as needed

Original cycle

Variable until target research endpoint achieved

Updated evidence review

Best-supported molecular regimen is afamelanotide 16 mg subcutaneous implant every 2 months; this does not validate reconstituted cosmetic self-injection vials.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

Subcutaneous implant in approved use

Frequency

Every 2 months in approved product regimen

Cycle logic

Scheduled implant therapy in approved use; cosmetic injection equivalence is not established

Why this cycle label

Evidence is for HCP-administered implant, not reconstituted self-injection.

How to read both ranges

Kept as previous guide context. Updated evidence distinguishes afamelanotide implant evidence from reconstituted vial use.

Evidence level

Approved product evidence for afamelanotide only

Monitoring / safety notes

Periodic skin examination, nevus changes, pigmentation response. Nausea, headache, implant-site effects, darkening of existing nevi.

COA check

Verify exact analogue identity and COA.

Storage

Store according to product label, COA, and laboratory SOPs

Melanocortin agonist research material used in pigmentation pathway studies.

Original guide dosage

Original guide range: 100-500 mcg daily until target pigmentation endpoint.

Original frequency

Daily loading, then 1-2x/week maintenance

Original cycle

Variable until target achieved

Updated evidence review

No validated cosmetic self-injection dose.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

SC in unlicensed cosmetic use, not an endorsed regimen

Frequency

No validated frequency

Cycle logic

No endorsed cosmetic cycle

Why this cycle label

Safety concerns and lack of validation mean grey-market practice should not be converted into recommendation.

How to read both ranges

Kept as previous guide context. Updated evidence says there is no validated cosmetic self-injection dose and safety concerns are substantial.

Evidence level

Unlicensed / unapproved use with safety concerns

Monitoring / safety notes

Skin changes, mole darkening, nausea, flushing, adverse reactions. Nausea, flushing, yawning, mole darkening, and concern around serious adverse events.

COA check

Verify exact analogue identity and COA.

Storage

Store according to product label, COA, and laboratory SOPs

IU-based hormone pathway research material used in LH-like signalling and fertility models.

Original guide dosage

Original guide range: 250-500 IU 2-3x/week or 1000-2000 IU weekly depending research context.

Original frequency

2-3x/week or indication-specific schedule

Original cycle

Varies widely by protocol

Updated evidence review

Indication-specific IU dosing; cannot be collapsed into one universal range.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

IM or SC depending protocol

Frequency

Repeated medical dosing with lab follow-up

Cycle logic

Not a simple short cycle; indication-specific regimen only

Why this cycle label

Male hypogonadotropic hypogonadism, fertility, and TRT fertility preservation use different schedules.

How to read both ranges

Kept as previous guide context. Updated evidence says HCG dosing is indication-specific and should not be collapsed into one universal range.

Evidence level

Approved hormone class, but exact regimen requires indication-specific label/guideline confirmation

Monitoring / safety notes

Hormones, fertility markers, clinical indication, lab follow-up. Hormonal adverse effects and lab-monitoring requirements.

COA check

IU-based item. This mg/mL calculator should not be used unless documentation supplies a mass-based conversion.

Storage

Store according to product label, COA, and laboratory SOPs

Neuropeptide research material used in HPG axis, LH, and FSH signalling studies.

Original guide dosage

Original guide range: 100-200 mcg, 2-3x/week.

Original frequency

2-3x/week

Original cycle

30 days on / off or adjunct research use

Updated evidence review

Early human work uses single IV infusion or bolus kisspeptin-54; no validated retail-vial SC regimen.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

IV most studied

Frequency

Acute or short experimental exposure

Cycle logic

Chronic self-cycling not validated

Why this cycle label

Human physiology studies do not translate into a retail-vial protocol.

How to read both ranges

Kept as previous guide context. Updated evidence anchors early human IV physiology studies, not validated retail-vial SC cycling.

Evidence level

Human physiology / early clinical work

Monitoring / safety notes

LH, FSH, sex hormones, indication-specific endocrine response. Hormonal effects and lack of chronic retail protocol validation.

COA check

Verify exact kisspeptin fragment against COA.

Storage

Store according to product label, COA, and laboratory SOPs

NNMT inhibitor research compound used in metabolic efficiency and body composition studies.

Original guide dosage

Original guide range: 50-100 mg daily.

Original frequency

Daily

Original cycle

4-8 weeks

Updated evidence review

No validated human dose established in this review.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

Human therapeutic route not established

Frequency

No validated frequency

Cycle logic

No validated cycle

Why this cycle label

Source gap remains; follow-up primary evidence needed before confident dosing language.

How to read both ranges

Kept as previous guide context. Updated evidence says no validated human dose established in this review.

Evidence level

Source gap in this pass; follow-up needed

Monitoring / safety notes

Metabolic study endpoints and product identity. Human dosing and safety standardization not established.

COA check

Small molecule research compound; verify CAS, formula, and molecular weight against COA.

Storage

Store according to product label, COA, and laboratory SOPs

Precision measuring accessory for laboratory preparation workflows.

Original guide dosage

Not applicable.

Original frequency

As required for research preparation workflow

Original cycle

Not applicable

Updated evidence review

Not applicable.

New vs old dosage comparison

No new dosage change added beyond the previous evidence review. Keep the original guide range visible and use the evidence section to explain uncertainty.

Route / format

Not applicable

Frequency

Not applicable

Cycle logic

Not applicable

Why this cycle label

Accessory only. Focus is aseptic handling and accurate reconstitution.

How to read both ranges

Accessory only. Focus remains accurate reconstitution, sterile handling, labeling, and storage.

Evidence level

Accessory / handling only

Monitoring / safety notes

Correct diluent, correct volume, labeling, storage, sterility, and documentation. Main risk is contamination or inaccurate reconstitution.

COA check

Accessory only. Not a peptide compound and not used for concentration calculation.

Storage

Store according to product label, COA, and laboratory SOPs